Statement: There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 19/70 (27.14%)   Febrile Neutropenia 24/70 (5.71%)   Pericarditis 21/70 (1.43%)   Sinus bradycardia 21/70 (1.43%)   Abdominal Pain 2/70 (2.86%)   Diarrhea 21/70 (1.43%)   Lower gastrointestinal hemorrhage 21/70 (1.43%)   Nausea 21/70 (1.43%)   Non Cardiac-Chest pain 22/70 (2.86%)   Fever 24/70 (5.71%)   Skin infection 41/70 (1.43%)   Neutrophil count decreased 31/70 (1.43%)